Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
95% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. SGEN: No Debt )
SGEN' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Equity to Asset 0.47
SGEN's Equity to Asset is ranked higher than
61% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. SGEN: 0.47 )
SGEN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.96
Current: 0.47

0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
62% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
SGEN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 10.99
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -27.52
SGEN's Operating margin (%) is ranked higher than
78% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. SGEN: -27.52 )
SGEN' s 10-Year Operating margin (%) Range
Min: -9958.59   Max: -23.35
Current: -27.52

-9958.59
-23.35
Net-margin (%) -27.12
SGEN's Net-margin (%) is ranked higher than
77% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. SGEN: -27.12 )
SGEN' s 10-Year Net-margin (%) Range
Min: -7917.17   Max: -23.22
Current: -27.12

-7917.17
-23.22
ROE (%) -36.99
SGEN's ROE (%) is ranked higher than
69% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. SGEN: -36.99 )
SGEN' s 10-Year ROE (%) Range
Min: -128.57   Max: -24.17
Current: -36.99

-128.57
-24.17
ROA (%) -17.50
SGEN's ROA (%) is ranked higher than
75% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. SGEN: -17.50 )
SGEN' s 10-Year ROA (%) Range
Min: -50.86   Max: -12
Current: -17.5

-50.86
-12
ROC (Joel Greenblatt) (%) -190.36
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. SGEN: -190.36 )
SGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -903.49   Max: -178.02
Current: -190.36

-903.49
-178.02
Revenue Growth (3Y)(%) 40.30
SGEN's Revenue Growth (3Y)(%) is ranked higher than
95% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. SGEN: 40.30 )
SGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.3   Max: 157.1
Current: 40.3

7.3
157.1
EBITDA Growth (3Y)(%) -24.70
SGEN's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. SGEN: -24.70 )
SGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.2   Max: 18
Current: -24.7

-30.2
18
EPS Growth (3Y)(%) -22.70
SGEN's EPS Growth (3Y)(%) is ranked higher than
65% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. SGEN: -22.70 )
SGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -34   Max: 27.9
Current: -22.7

-34
27.9
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SGEN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 399,490 sh (+46.34%)
Jim Simons Sold Out
Ray Dalio Sold Out
Columbia Wanger 6,610,000 sh (-0.24%)
PRIMECAP Management 10,895,800 sh (-1.01%)
» More
Q3 2014

SGEN Guru Trades in Q3 2014

Ray Dalio 6,140 sh (New)
Manning & Napier Advisors, Inc 485,810 sh (+21.61%)
PRIMECAP Management 10,954,900 sh (+0.54%)
Columbia Wanger 5,155,000 sh (-22.01%)
» More
Q4 2014

SGEN Guru Trades in Q4 2014

PRIMECAP Management 11,178,050 sh (+2.04%)
Manning & Napier Advisors, Inc 485,810 sh (unchged)
Ray Dalio Sold Out
Columbia Wanger Sold Out
Columbia Wanger 4,474,100 sh (-13.21%)
» More
Q1 2015

SGEN Guru Trades in Q1 2015

PRIMECAP Management 11,836,575 sh (+5.89%)
Manning & Napier Advisors, Inc 492,690 sh (+1.42%)
Columbia Wanger 3,408,200 sh (-23.82%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 26.10
SGEN's P/B is ranked lower than
59% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. SGEN: 26.10 )
SGEN' s 10-Year P/B Range
Min: 1.64   Max: 29.21
Current: 26.1

1.64
29.21
P/S 18.00
SGEN's P/S is ranked higher than
65% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. SGEN: 18.00 )
SGEN' s 10-Year P/S Range
Min: 9.98   Max: 45.83
Current: 18

9.98
45.83
EV-to-EBIT -57.56
SGEN's EV-to-EBIT is ranked lower than
53% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SGEN: -57.56 )
SGEN' s 10-Year EV-to-EBIT Range
Min: -102.6   Max: -2.8
Current: -57.56

-102.6
-2.8
Current Ratio 3.10
SGEN's Current Ratio is ranked higher than
67% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. SGEN: 3.10 )
SGEN' s 10-Year Current Ratio Range
Min: 2.75   Max: 30.03
Current: 3.1

2.75
30.03
Quick Ratio 2.76
SGEN's Quick Ratio is ranked higher than
66% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. SGEN: 2.76 )
SGEN' s 10-Year Quick Ratio Range
Min: 2.75   Max: 30.03
Current: 2.76

2.75
30.03
Days Inventory 428.00
SGEN's Days Inventory is ranked higher than
77% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SGEN: 428.00 )
SGEN' s 10-Year Days Inventory Range
Min: 442.93   Max: 639.76
Current: 428

442.93
639.76
Days Sales Outstanding 60.20
SGEN's Days Sales Outstanding is ranked higher than
84% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. SGEN: 60.20 )
SGEN' s 10-Year Days Sales Outstanding Range
Min: 25.55   Max: 1028.64
Current: 60.2

25.55
1028.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 93.10
SGEN's Price/Net Cash is ranked higher than
56% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. SGEN: 93.10 )
SGEN' s 10-Year Price/Net Cash Range
Min: 2.12   Max: 75.21
Current: 93.1

2.12
75.21
Price/Net Current Asset Value 46.10
SGEN's Price/Net Current Asset Value is ranked higher than
56% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. SGEN: 46.10 )
SGEN' s 10-Year Price/Net Current Asset Value Range
Min: 2.09   Max: 447
Current: 46.1

2.09
447
Price/Tangible Book 26.00
SGEN's Price/Tangible Book is ranked lower than
57% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. SGEN: 26.00 )
SGEN' s 10-Year Price/Tangible Book Range
Min: 1.78   Max: 24.23
Current: 26

1.78
24.23
Price/Median PS Value 0.90
SGEN's Price/Median PS Value is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. SGEN: 0.90 )
SGEN' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 27.14
Current: 0.9

0.49
27.14
Earnings Yield (Greenblatt) -1.70
SGEN's Earnings Yield (Greenblatt) is ranked higher than
80% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. SGEN: -1.70 )
SGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.3   Max: 0
Current: -1.7

-2.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. In August 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRIS, or brentuximab vedotin, in two indications; the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Companys proprietary technology. The Company collaborated with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
Comment for Companies Ranked by Business Predictability Jan 03 2013 
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 

More From Other Websites
4 Momentum Stocks Breaking Out and Poised to Move Higher May 21 2015
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 19 2015
SLU vs. Bothell: The region's two hot biotech real estate markets go head to head May 18 2015
15 biotech stocks to put on your watch list now May 15 2015
Seattle Genetics' Top Holder Buys $37M More Stock May 13 2015
5 Stocks Insiders Love Right Now May 13 2015
Biotech leaders sound off on how to create anchor companies, stable ecosystem in Seattle May 11 2015
Seattle Genetics (SGEN) in Focus: Stock Up 8.1% - Tale of the Tape May 11 2015
Insider Buying Massive This Week as Market Roller Coaster Continues May 09 2015
Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks May 06 2015
Seattle Genetics Posts Narrower-than-Expected Loss in Q1 - Analyst Blog May 04 2015
10-Q for Seattle Genetics, Inc. May 03 2015
SEATTLE GENETICS INC /WA Files SEC form 10-Q, Quarterly Report May 01 2015
Seattle Genetics reports 1Q loss Apr 30 2015
Seattle Genetics reports 1Q loss Apr 30 2015
Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today Apr 30 2015
Seattle Genetics Reports First Quarter 2015 Financial Results Apr 30 2015
4:21 pm Seattle Genetics beats by $0.02, beats on revs Apr 30 2015
SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 30 2015
Seattle Genetics Reports First Quarter 2015 Financial Results Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK